YORK, PA, December 28, 2023. Today, HR Pharmaceuticals, Inc. (HRP) announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis’s Dual Balloon Catheter (Duette™). Under the terms of the agreement, HRP will have exclusive commercialization rights in North America. This product expands HRP’s growing urological portfolio across the continuum of care, providing a novel design to help address adverse events associated with Foley catheterization, which is critically important for specific patient populations.
“The Dual Balloon Catheter has demonstrated significant benefits compared to traditional Foley catheters, leading to better patient outcomes. Specifically, we see a great opportunity for patients requiring indwelling catheterization greater than five days. This product will become an important part of our broader urology strategy over the next 12 months,” states Colby Wiesman, President of HR Pharmaceuticals, Inc.
“The Dual Balloon Catheter technology, a brainchild of my father, Dr. Bruce Wiita, a practicing urologist and decorated Vietnam veteran, was born out of a genuine desire to improve the quality of life for patients enduring prolonged catheterization and to alleviate the strains it places on the healthcare system,” says Gregory Wiita, CEO and Founder at Poiesis Medical LLC. “We are excited about this new chapter with HR Pharmaceuticals and the potential of the technology to make a meaningful impact in patient care.” HRP will begin processing North American orders for the Duette Dual Balloon Catheters starting January 2, 2024. Duette is available at most national distributors, including Cardinal Health, McKesson, Medline, and Owens & Minor. For further assistance or additional information, please contact HRP at customercare@hrpharma.com or 800.302.1110.
